As discussed previously, the ratio of BCL2, BCL-XL and MCL1 expression in myeloma cell lines, primary cells and patient samples in clinical trials has been associated with venetoclax sensitivity, suggesting variable relative dependencies on these pro-survival proteins as a driver of intrinsic resistance [113–115, 122, 123, 132]. The gene discussed is BCL2; the disease is plasma cell myeloma.